The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Subscribe To Our Newsletter & Stay Updated
